These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 9104946)
1. Immunostaining of the von Hippel-Lindau gene product in normal and neoplastic human tissues. Corless CL; Kibel AS; Iliopoulos O; Kaelin WG Hum Pathol; 1997 Apr; 28(4):459-64. PubMed ID: 9104946 [TBL] [Abstract][Full Text] [Related]
2. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293 [TBL] [Abstract][Full Text] [Related]
3. Subcellular localization of the von Hippel-Lindau disease gene product is cell cycle-dependent. Ye Y; Vasavada S; Kuzmin I; Stackhouse T; Zbar B; Williams BR Int J Cancer; 1998 Sep; 78(1):62-9. PubMed ID: 9724095 [TBL] [Abstract][Full Text] [Related]
4. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma. Clifford SC; Astuti D; Hooper L; Maxwell PH; Ratcliffe PJ; Maher ER Oncogene; 2001 Aug; 20(36):5067-74. PubMed ID: 11526493 [TBL] [Abstract][Full Text] [Related]
5. Identification of a novel protein (VBP-1) binding to the von Hippel-Lindau (VHL) tumor suppressor gene product. Tsuchiya H; Iseda T; Hino O Cancer Res; 1996 Jul; 56(13):2881-5. PubMed ID: 8674032 [TBL] [Abstract][Full Text] [Related]
6. The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Pause A; Lee S; Worrell RA; Chen DY; Burgess WH; Linehan WM; Klausner RD Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2156-61. PubMed ID: 9122164 [TBL] [Abstract][Full Text] [Related]
7. The von Hippel-Lindau protein interacts with heteronuclear ribonucleoprotein a2 and regulates its expression. Pioli PA; Rigby WF J Biol Chem; 2001 Oct; 276(43):40346-52. PubMed ID: 11517223 [TBL] [Abstract][Full Text] [Related]
8. von Hippel-Lindau protein mutants linked to type 2C VHL disease preserve the ability to downregulate HIF. Hoffman MA; Ohh M; Yang H; Klco JM; Ivan M; Kaelin WG Hum Mol Genet; 2001 May; 10(10):1019-27. PubMed ID: 11331612 [TBL] [Abstract][Full Text] [Related]
9. Relevance of nuclear and cytoplasmic von hippel lindau protein expression for renal carcinoma progression. Schraml P; Hergovich A; Hatz F; Amin MB; Lim SD; Krek W; Mihatsch MJ; Moch H Am J Pathol; 2003 Sep; 163(3):1013-20. PubMed ID: 12937142 [TBL] [Abstract][Full Text] [Related]
10. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Kaelin WG Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019 [TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo models analyzing von Hippel-Lindau disease-specific mutations. Rathmell WK; Hickey MM; Bezman NA; Chmielecki CA; Carraway NC; Simon MC Cancer Res; 2004 Dec; 64(23):8595-603. PubMed ID: 15574766 [TBL] [Abstract][Full Text] [Related]
12. Expression pattern of the von Hippel-Lindau protein in human tissues. Los M; Jansen GH; Kaelin WG; Lips CJ; Blijham GH; Voest EE Lab Invest; 1996 Aug; 75(2):231-8. PubMed ID: 8765323 [TBL] [Abstract][Full Text] [Related]
13. Transcription-dependent nuclear-cytoplasmic trafficking is required for the function of the von Hippel-Lindau tumor suppressor protein. Lee S; Neumann M; Stearman R; Stauber R; Pause A; Pavlakis GN; Klausner RD Mol Cell Biol; 1999 Feb; 19(2):1486-97. PubMed ID: 9891082 [TBL] [Abstract][Full Text] [Related]
14. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones. Tsuchiya MI; Okuda H; Takaki Y; Baba M; Hirai S; Ohno S; Shuin T Oncol Rep; 2005 Jun; 13(6):1033-41. PubMed ID: 15870918 [TBL] [Abstract][Full Text] [Related]
15. Tumour suppression by the human von Hippel-Lindau gene product. Iliopoulos O; Kibel A; Gray S; Kaelin WG Nat Med; 1995 Aug; 1(8):822-6. PubMed ID: 7585187 [TBL] [Abstract][Full Text] [Related]
16. Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Iwai K; Yamanaka K; Kamura T; Minato N; Conaway RC; Conaway JW; Klausner RD; Pause A Proc Natl Acad Sci U S A; 1999 Oct; 96(22):12436-41. PubMed ID: 10535940 [TBL] [Abstract][Full Text] [Related]
17. Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density. Lee S; Chen DY; Humphrey JS; Gnarra JR; Linehan WM; Klausner RD Proc Natl Acad Sci U S A; 1996 Mar; 93(5):1770-5. PubMed ID: 8700833 [TBL] [Abstract][Full Text] [Related]
18. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Kibel A; Iliopoulos O; DeCaprio JA; Kaelin WG Science; 1995 Sep; 269(5229):1444-6. PubMed ID: 7660130 [TBL] [Abstract][Full Text] [Related]
19. Identification of novel VHL target genes and relationship to hypoxic response pathways. Maina EN; Morris MR; Zatyka M; Raval RR; Banks RE; Richards FM; Johnson CM; Maher ER Oncogene; 2005 Jun; 24(28):4549-58. PubMed ID: 15824735 [TBL] [Abstract][Full Text] [Related]
20. Hepatocyte growth factor-stimulated renal tubular mitogenesis: effects on expression of c-myc, c-fos, c-met, VEGF and the VHL tumour-suppressor and related genes. Clifford SC; Czapla K; Richards FM; O'Donoghue DJ; Maher ER Br J Cancer; 1998 May; 77(9):1420-8. PubMed ID: 9652757 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]